GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Valuation Rank

Actavia Life Sciences (Actavia Life Sciences) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Actavia Life Sciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Actavia Life Sciences (Actavia Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Valuation Rank
Comparable Companies
BWV FNCH CWBR NRSN EMMA CELZ MNPR AMTI PYPD CYCN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170
Website
https://www.rasna.com
Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.